WASHINGTON D.C. — C.R. Bard’s efforts to once again delay the federal bellwether trials scheduled for this year were stymied in court.

Recently, the federal judge overseeing the C.R. Bard transvaginal mesh cases commented on how the company was at risk of facing billions of dollars in liability and should seriously consider reaching a settlement with all its victims. This comment was leaked to the press in early December. C.R. Bard moved to suspend future trials, claiming the judge’s statement was distorted by the press and financial analysts in a Bloomberg article. While it is rare for a judge to warn a company of the consequences of failing to resolve its lawsuits, it is also illegal. Judge Joseph Goodwin denied the motion to halt the trials.

C.R. Bard and Defective Mesh Devices

C.R. Bard is one of multiple medical device manufacturers that is being sued in federal court for its defective transvaginal or pelvic mesh devices. The federal trials are scheduled to start early this year and span 7 manufacturers and over 49,000 cases. The company faces more than 12,000 personal injury lawsuits claiming negligence, failure to warn, manufacturing and design defect, and punitive damages. The possibility of facing billions of dollars in verdicts would seriously risk driving the company into bankruptcy. C.R. Bard already agreed to settle $21 million for 500 lawsuits in October 2014, the first large settlement by the company with regards to its transvaginal mesh cases.

C.R. Bard began manufacturing and selling transvaginal mesh products in the late 1990s. This synthetic netting is used by surgeons to treat pelvic organ prolapse – which is when the pelvic muscles weaken to the point the organs drop into the vaginal cavity. Unfortunately, the mesh has been found to cause various complications such as prolapse, incontinence, infection, pain, bleeding, sexual problems, internal scarring, and organ perforation.

C.R. Bard has produced numerous transvaginal mesh products that have been found to cause injury. They include the Pelvilace, Pelvitex, Pelvisoft BioMesh, Pelvicol Acellular, Collagen Matrix, and Avaulta lines. The company was hit with a $3.6 million verdict in 2012 – the very first transvaginal mesh verdict. C.R. Bard stopped selling the Avaulta Plus line shortly thereafter in response to the verdict and to the FDA’s order requiring all transvaginal mesh makers to study the rates of organ damage, infection, and pain due to their mesh devices.

If you or a loved one has a C.R. Bard transvaginal or pelvic mesh device and is suffering complications, please contact an experienced attorney. You may be entitled to compensation for your injuries.

Our Lawyers Can Help

Our dangerous device attorneys can help if you or someone you care about was harmed by a transvaginal mesh implant. Lawsuits have been filed against the device maker by both patients and their families seeking compensation for injuries caused by the dangerous device. You may be entitled to a settlement. We do not charge any legal fees unless you receive a settlement and we pay all of the case costs. If your claim is not successful for any reason, you do not owe us anything. We put it all in writing for you. Our transvaginal mesh lawyers will help you file your lawsuit.

Our No Fee Promise on Transvaginal Mesh Cases

You can afford to have our great team of lawyers on your side. When you choose us, it literally costs nothing to get started. We promise you in writing:

  • No money to get started
  • We pay all case costs and expenses
  • No legal fees whatsoever unless you receive a settlement
  • Phone calls are always free.

Start Your Transvaginal Mesh Claim

Our transvaginal mesh lawyers will help you file your lawsuit. To get started, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call (866) 280-4722 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have claim, we will start immediately.

WARNING: There are strict time deadlines for filing transvaginal mesh lawsuit claims.

  • Was this information helpful?
  • Yes   No